Streetbeat News

Products Services

CCCC

C4 Therapeutics is set to present preliminary Phase 1 clinical data for its CFT1946 monotherapy at the ESMO Congress 2024. This development is significant for the company's pipeline and future prospects.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 7:20 am

MGNX

MacroGenics, Inc. will present Phase 2 results of its cancer treatment, vobramitamab duocarmazine, at the ESMO 2024 Congress. This presentation could impact the company's stock as it showcases their progress in treating metastatic castration-resistant prostate cancer.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 7:15 am

NTRA

Natera, Inc. will present significant findings from the CIRCULATE-Japan trial at the ESMO 2024 Congress, highlighting a 10X survival advantage with its Signatera test. The presentations will include data on colorectal cancer, breast cancer, and squamous cell carcinoma.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 7:05 am

EYEN

Formosa Pharma and Eyenovia are set to launch a new FDA-approved ophthalmic drug, APP13007, in the US. The drug, developed using Formosa's APNT® nanotechnology, offers a convenient dosing regimen and targets a $1.3 billion market.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 7:02 am

TDY

Teledyne FLIR Defense, a division of Teledyne Technologies, has secured a contract worth approximately $21 million to supply advanced surveillance systems to the Japan Maritime Self-Defense Force. The systems, known as Star SAFIRE 380-HLD, offer ultra-long-range performance and laser targeting capabilities.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 6:58 am

MASI

Masimo's SafetyNet platform is being used by Saint-Denis Hospital to enable early ICU discharge for premature babies, allowing them to be monitored at home.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 6:58 am

PLTR

LifeWallet has secured a key waiver from its largest creditor and launched new agreements with health plans and insurers. In partnership with Palantir Technologies, LifeWallet is enhancing its 'Chase to Pay' model with a sophisticated clearinghouse system. This initiative is expected to generate revenue through fees on savings from unnecessary Medicare secondary payments.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 6:37 am

AAPL

ARM

Apple Inc. is set to launch the iPhone 16 series featuring ARM Holdings' next-gen AI chip technology, enhancing AI capabilities. The A18 chip, based on Arm's V9 architecture, will be unveiled at Apple's 'Glowtime' event. This move aligns with Apple's strategy to integrate advanced AI features into its products.

Portfolio Pulse from Ananya Gairola

September 09, 2024 | 6:29 am

TSLA

Tesla plans to expand its Supercharger network, with CEO Elon Musk seeking input on new locations. Despite past layoffs affecting the supercharging team, Tesla aims to invest $500 million in network expansion this year. The growth rate of Superchargers has slowed, but the company remains committed to increasing its network.

Portfolio Pulse from Anan Ashraf

September 09, 2024 | 6:27 am

PLTR

Palantir Technologies (NASDAQ:PLTR) will be added to the S&P 500 Index, marking a significant milestone for the company. Analyst Daniel Ives from Wedbush views this as a validation of Palantir's growth and profitability potential, driven by its AI platform and U.S. Commercial business. The inclusion is expected to boost Palantir's momentum, especially in the federal sector, and marks the start of a multi-year growth cycle. Wedbush has an Outperform rating and a $38 price target for Palantir.

Portfolio Pulse from Shanthi Rexaline

September 09, 2024 | 6:23 am